Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee

Arthritis and Rheumatism

Volumn 40, Issue 5, 1997, Pages 893-900

  Bakker, Andrew C ^a,c   Joosten, Leo A B ^a   Arntz, Onno J ^a   Helsen, Monique M A ^a   Bendele, Alison M ^b   Van de Loo, Fons A J ^a   Van den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMGEN INC   (United States)

^c Department of Rheumatology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CARTILAGE CELL; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNEE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030973263     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400517     Document Type: Article

References (24)

1. Piquet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510-514, 1992
2. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89:9784-9788, 1992
3. Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151:6602-6607, 1993
4. Geiger T, Towbin H, Cosenti-Vargas A, Zingel O, Arnold J, Rordorf C, Glatt M, Vosbeck K: Neutralization of interleukin-1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol 11:515-522, 1993
5. Van den Berg WB, Joosten LAB, Helsen MMA, van de Loo FAJ: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95:237-243, 1994
6. Van de Loo FAJ, Arntz OJ, Otterness IG, van den Berg WB: Protection against cartilage proteoglycan synthesis inhibition by anti-interleukin 1 antibodies in experimental arthritis. J Rheumatol 19:348-356, 1992
7. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB: Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induccd arthritis. Arthritis Rheum 38:164-172, 1995
8. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 39:797-809, 1996
9. Drevlow BE, Capezio J, Lovis R, Jacobs C, Landay A, Pope RM: Phase I study of recombinant human interleukin-I receptor (RHUIL-1R) administered intra-articularly in active rheumatoid arthritis (abstract). Arthritis Rheum 36 (suppl 9):S39, 1993
10. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalane M, and the IL-1Ra Arthritis Study Group: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39:1092-1101, 1996
11. Staite ND, Richard KA, Aspar DG, Franz KA, Galinet LA, Dunn CJ: Induction of an acute erosive monoarticular arthritis in mice by interleukin-1 and methylated bovine serum albumin. Arthritis Rheum 33:253-260, 1990
12. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen J, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woodey JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1-110, 1994
13. Bandara G, Robbins PD, Georgescu HI, Mueller GM, Glorioso JC, Evans CH: Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 11:227-231, 1992
14. Hung GL, Galea Lauri J, Mueller GM, Georgescu HI, Larkin LA, Suchanek MK, Tindal MH, Robbins PD, Evans CH: Suppression of intraarticular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther 1:64-69, 1994
15. Bandara G, Mueller GM, Galea Lauri J, Tindal MH, Georgescu HI, Suchanek MK, Hung GL, Glorioso JC, Robbins PD, Evans CH: Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 90:10764-10768, 1993
16. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH: Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 156:3558-3562, 1996
17. Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS, Haskill JS, Schwab JH: Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A 93:402-406, 1996
18. Ivanyl I: Antigenic phenotype of NIH/3T3 cell line. J Natl Cancer Inst 79:149-153, 1987
19. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA: Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 78:1275-1281, 1991
20. Van Noorden CJF, Vogels IMC: Enzyme histochemical reactions in unfixed and undecalcified cryostat sections of mouse knee joints with special reference to arthritic lesions. Histochemistry 6:127-133, 1986
21. Van den Berg WB, van Beusekom HJ, van de Putte LBA, Zwarts WA, van der Sluis M: Antigen handling in antigen-induced arthritis in mice: an autoradiographic and immunofluorescence study using whole joint sections. Am J Pathol 108:9-16, 1982
22. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvailer NJ, Arend WP: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 37:644-652, 1994
23. Ku G, Faust T, Lauffer LL, Livingston DJ, Harding MW: Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 8:377-386, 1996
24. Joosten LAB, Helsen MMA, van den Berg WB: Accelerated onset of collagen-induced arthritis by remote inflammation. Clin Exp Immunol 97:204-211, 1994